



ASX: LCT - OTCQX: LVCLY

Diabetes – Neurodegenerative Diseases – Cell Encapsulation

Six reasons to invest in Living Cell Technologies

ALSIS 2012



#1

A company on a mission

Cell based therapies to improve the lives of people with serious disease


IP: US, EU, world



GMP manufacture



Encapsulation



#2

A lead product in late stage clinical development

DIABECCELL[®] for the treatment of unstable Type I Diabetes

Feature	
Product	Encapsulated porcine islets
Target market	Unstable Type I diabetes – 1.6m patients
Product differentiator	β -cell replacement therapy without immunosuppression
Stage of development	Phase III – expected Argentina, Germany and NZ during 2013.
Expected date of filing	Early 2016 in NZ and EU

#3

A major pharmaceutical partner

- Otsuka Pharmaceutical Factory (OPF)
 - Focus on DIABECCELL product only
- AUD25m to fund DIABECCELL
 - Zero LCT cash burn to move DIABECCELL to market
- LCT receives **50%** of worldwide profits
- LCT retains exclusive, perpetual license to exploit all IP in all other disease fields



#4

Second product entering clinic in 2013


NTCELL™ for the treatment of Parkinson's

Feature	
Product	Encapsulated porcine choroid plexus cells
Target market	Patients with mid-stage Parkinson's disease - 1.6m patients
Product differentiator	Restoration of normal function by regeneration of appropriate neural pathways
Stage of development	Phase I expected commence in NZ 2013
Expected date of filing for registration	2018




NTCELL - A powerful mechanism of action

Hundreds of regenerative growth factors & protective agents



#5

NTCELL will be useful in a range of diseases




#5

NTCELL will be useful in a range of diseases

UNTREATED

TREATED




Parkinson's primate

(Lin et al., Regenerative medicine Submitted 2012)



Huntington's primate

(Emerich et al., (2006) Neurobiology of Disease 23:471-480)




Stroke rat

(Borlongan et al., (2004) Stroke 35:2206-2210)


#5

NTCELL will be useful in a range of diseases



Wound healing Rats

Thanos et al., Cell Transplantation (2009) 18:
1395-1409



Hearing loss - cats

Wise et al., Neurotherapeutics
(2011) 8:774-787

#6

Sound finances & safe hands

Fundamental	Details
Shares outstanding	357m
5day VWAP (29/10/12)	0.051
52 wk Hi/Low	0.13-0.04
Cash on hand (AUD) (30/9/12)	2.9m
Current burn/annum (AUD)	1.6m
Estimate first product revenues	2016

Board

Roy Austin (Chair)
Professor Bernie Tuch
Robert Willcocks
Laurie Hunter
Professor Bob Elliott

Management

Dr Andrea Grant (CEO)
Professor Bob Elliott (acting CSMO)
John Cowan (Finance)
Peter Hosking (Operations)
Isobel Cooper (Animal welfare)



SAFE HARBOR STATEMENT

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

